

Immune profiling platform

- Cutting-edge technologies and assay development
- Efficient project management
- Experienced highly experienced team
- Expedite the discovery and development of novel therapeutics

Flow Cytometry



Cytek Aurora (40 colors)
BD LSR Fortessa (18 colors)
BD LSR Fortessa X20 (18 colors)
BD Canto plus (10 colors)
BD Canto II (8 colors)
BD FACS Aria II (18 colors)
IntelliCyt iQue3

- Tumor infiltrating lymphocyte (TIL) analysis
- Immune checkpoint analysis
- T cell activation and proliferation
- PhosphoFlow

Multiplex IF



Akoya Polaris
HALO

- Tumor microenvironment analysis
- Area quantification
- Immune cell scoring
- Immune cell interaction
- Biomarker analysis

NanoString



nCounter PrepStation
nCounter Digital Analyzer

- Expression profiling
- Biomarker discovery
- Target identification
- Mechanism of action studies
- Time series analysis

Cytokine Profiling



MSD SQ120
Luminex 200
Olink Q100
ELISA
FCM-based CBA

- Immune activation monitoring
- Immune cell function analysis
- Biomarker identification

Broad application



Target discovery and validation

Help identify and validate drug targets by measuring the expression levels of immune-related genes and proteins in relevant biological pathways or networks.



Assessing drug efficacy

Assess the efficacy of drugs by measuring changes in the immune system or microenvironment following treatment.



Action mechanism

Identify potential mechanisms of action of drugs and guide the development of combination therapies.



Biomarker discovery


Identify biomarkers that are predictive of drug response or disease progression. Support patient stratification for clinical trials and guide the development of new therapies.



Contact us

Technical: Pharmacology-BD-Translation@wuxiapptec.com
BD USA: mahnaz_arjomand@wuxiapptec.com
BD EU/UK/Israel: dave_madge@wuxiapptec.com

BD China: xu_longji@wuxiapptec.com
BD Japan: fumio_itoh@wuxiapptec.com
BD Korea: sycho@wuxiapptec.com



Target Gene Wildtype

Condition

- Control
- Treatment

Target Gene Mutated (Dysfunction)

Condition

- Control
- Treatment

Figure 1A: Tumor Volume (mm³) vs. Days after the start of treatment

Days after the start of treatment	Control (mm ³)	TA (mm ³)
0	~100	~100
5	~150	~100
10	~250	~100
15	~400	~100
20	~1500	~100

Figure 1B: Percentage (%) of Immune Cell Infiltration

Cell Type	Control (%)	Treatment (%)
T in CD45 ⁺	~18	~45**
CD8T in CD45 ⁺	~12	~25*
CD4T in CD45 ⁺	~8	~22**
CD4T in T	~55	~40*
CD8T in T	~32	~50**
Treg in CD4T	~5	~2*

Figure 2 consists of two panels. The left panel is a fluorescence microscopy image showing CD8 T cells stained for CD64 (green), CD8 (yellow), CD68 (blue), PD-L1 (cyan), and Pan-CK (red). The right panel is a bar graph showing the positive rate (%) of CD64 expression in CD8 T cells for Adeno (red) and Squamous (blue) groups across four conditions: PD-1+ Tim-3+, PD-1+ Tim-3-, PD-1- Lag-3+, and PD-1+ Lag-3+.

Condition	Adeno (%)	Squamous (%)
PD-1+ Tim-3+	~18	~12
PD-1+ Tim-3-	~31	~37
PD-1- Lag-3+	~8	~6
PD-1+ Lag-3+	~41	~43

- Cutting-edge technologies – utilizing multidisciplinary and advanced technologies for precise and in-depth immune profiling.
- End-to-end solution – from study design and sample processing, to data analysis, interpretation and reporting.
- Team excellence – highly trained and experienced team specialized in immune profiling research, with a proven track record of supporting successful drug discovery efforts
- Our platform has been extensively employed in different stages of drug discovery programs across a variety of therapeutic areas, including oncology, autoimmune diseases, and infectious diseases.